Welcome to BioLegend’s one-of-a-kind advanced search. Search by any one of the single fields below or narrow down your searches by using multiple parameters. Looking for an anti-mouse NK cell antibody for IHC? Or looking for a FITC-conjugated antibody against a human marker for dendritic cells to use for flow cytometry? Only BioLegend’s advanced search can provide you with the best answers. If you have further questions, please contact our technical service team at 858-768-5801.
Use this document lookup tool to find Current Product Datasheets, Certificates of Analysis, or MSDS for any antibody products you have purchased from BioLegend.
Use the search box below to perform a site search of BioLegend.com powered by Google™.
Recombinant Human IL-27 (carrier-free)
Recombinant Human IL-27 (carrier-free)
589202
10 µg
¥57,000
589204
25 µg
¥97,000
Product Details
Source:
The human IL-27 consists of two subunits linked via a 4x(GGGS) bridge: Human CD33 signal peptide (Met1-Ala16) human EBV-3 induced gene 3 (EBI3) (Accession# NM_005755 Arg21 – Lis229) and human p28 (Accession# NM_145659 Phe29 - Pro243) 10 His-tag. Mouse I
Formulation:
0.22 µm filtered protein solution is in 20 mM NaHPO4, pH 6, 0.60 M NaCl.
Endotoxin Level:
Less than 0.01 ng per µg cytokine as determined by the LAL method.
Concentration:
10 and 25 µg sizes are bottled at 100 µg/mL.
Storage & Handling:
Unopened vial can be stored at -20°C for six months or at -70°C for one year. For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 µg/mL in buffer containing carrier protein such as 1% BSA or HSA or 10% FBS. After dilution, the cytokine can be stored at 4°C for one month or from -20°C to -70°C for up to 3 months. Avoid repeated freeze/thaw cycles.
Activity:
ED50 = 60 - 90 ng/ml, corresponding to a specific activity of 1.1 - 1.7 x 104 units/mg, as determined by mouse splenocytes IL-2 inhibition induced by hIL-27 in mouse splenocytes activated with anti-CD3 and anti-CD28 antibodies.
Inhibition of IL-2 production by human IL-27 in activated splenocytes
Description:
IL-27 is a heterodimeric cytokine that consists of EBI3, an IL-12p40-related protein, and p28, an IL-12p35-related polypeptide. IL-27 can be allocated to the IL-6/IL-12 superfamily of cytokines which also includes IL-23. This family is defined based on similarities in the structural motifs of the ligands, such as a common four-helix bundle and their receptors, which contain a hematopoietin receptor domain. IL-27 signaling occurs via a receptor complex composed of the signal transducing receptor chains WSX-1 and glycoprotein (gp) 130. Whereas WSX-1 is the IL-27–specific receptor chain, gp130 is the common receptor subunit of IL-6 type cytokines. IL-27 is expressed at sites of inflammation in cytokine-driven autoimmune/inflammatory diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, and sarcoidosis.
Other Names:
IL-27 (28K subunit), IL-27 (EBI3 subunit)
Structure:
Heterodimer
Distribution:
Monocytes, macrophages, DC
Function:
IL-27 triggers rapid clonal expansion of antigen-specific naive human and mouse CD4 T cell. IL-27 promotes the early Th1 differentiation through up-regulation of ICAM-1 and T-bet, and suppresses the differentiation to Th2 and Th17. In addition, IL-27 suppresses the cytokine production by activated CD4+ T cells in vitro, and TNF-α and IL-12 production by macrophages. This suppressive mechanism is considered to be mediated through IL-10. IL-27 plays a dominant function together with TGF-β in generating IL-10-producing anti-inflammatory Tr1 cells. Additionally, IL-27 exerts IFN-like functions in liver cells, and is a negative regulator of human neutrophils function. IL-27 is predominantly produced early after stimulation of APCs by TLR ligands or infectious agents, and it is induced by TNF-α in human macrophages.
Ligand Receptor:
IL-27RA (also known as WSX-1 or TCCR) paired with gp130
Interaction:
Activated T cells, resting NK cells, resting NKT cells, neutrophils, eosinophils, mast cells, hepatic stellate cells, hepatoma cells, and hepatocytes
Antigen References:
1. Pflanz S, et al. 2002. Immunity 16:779. 2. Owaki. T, et al. 2005. J. Immunol. 175:2191. 3. Batten M, et al. 2006. Nat. Immunol. 7:929. 4. Villarino VA, et al. 2006. J. Immunol. 176:237. 5. Stumhofer JS, et al. 2007. Nat. Immunol. 8:1363. 6. Awasthi A, et al. 2007. Nat. Immunol. 8:1380. 7. Pot C, et al. 2009. J. Immunol. 183:797. 8. Bender H, et al. 2009. Hepatology 50:585. 9. Kalliolias GD, et al. 2010. J. Immunol. PMID:20971923.
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/terms). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.
